Loading…
Employees: 1,887
Size GuiZhou SanLi Pharmaceutical (603439.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $657M, the 3225th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥10.84 on 6 Nov 2026.
Performance Over six months the shares fell 3.6%, against -14.6% for the median peer and -16.4% for the China market (cap-weighted) — 6th highest of 21 in its peer set.
Growth Revenue fell 5.7% over the last twelve months (peer median +10.1%); the operating margin is 5.0% (peer median 5.8%).
Valuation It trades at 30.1× forward earnings against a peer median of 15.2× (3rd most expensive of 8).
Price implies For today's price to make sense, revenue must grow about 23% a year for seven years (Req g). Recent delivered growth is +22%, so the hurdle is +1 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 4.0 points below its cost of capital (9.1% WACC).
Next results Next results expected around 28 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.64B | CN¥1.69B | CN¥2.13B | CN¥1.62B | CN¥1.19B |
| Revenue growth | — | -21% | +31% | +36% | — |
| Gross profit | CN¥1.20B | CN¥1.14B | CN¥1.44B | CN¥1.16B | CN¥843M |
| EBITDA | n/a | CN¥262M | CN¥400M | CN¥307M | CN¥222M |
| Net income | CN¥52.8M | CN¥46.3M | CN¥274M | CN¥293M | CN¥201M |
| Free cash flow | CN¥183M | CN¥139M | CN¥63.5M | CN¥169M | CN¥175M |
| Capital expenditure | CN¥22.9M | CN¥25.8M | CN¥45.2M | CN¥109M | CN¥120M |
| Total debt | CN¥668M | CN¥795M | CN¥728M | CN¥610M | CN¥235M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 603439.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -14.3% | -5.4% | 4th lowest of 21 |
| 6-month return | -3.6% | -14.6% | 6th highest of 21 |
| Distance from 52-week high | -37.9% | -34.4% | 9th lowest of 21 |
| Revenue growth (TTM) | -5.7% | +10.1% | 3rd lowest of 17 |
| Operating margin | 5.0% | 5.8% | 9th highest of 17 |
| Forward P/E | 30.1× | 15.2× | 3rd most expensive of 8 |
| Growth the price implies (Req g, 7 yrs) | 23.2% | 1.1% | 4th most demanding of 10 |
| Growth delivered (Del g) | +21.9% | +6.4% | highest of 10 |
| Hurdle (Req g minus delivered) | +1.2 pp | +15.6 pp | 4th least demanding of 10 |
| ROIC minus cost of capital | -4.0 pp | -3.9 pp | 8th lowest of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| GuiZhou SanLi Pharmaceutical 603439.SS | China | $657M | -4% | -6% | 5% | 30.1× | 23.2% | +21.9% |
| Fuan Pharmaceutical (Group) 300194.SZ | China | $653M | -11% | -3% | -1% | n/a | 12.1% | -5.9% |
| Shandong Jincheng Pharmaceutical 300233.SZ | China | $661M | -25% | +2% | 4% | n/a | 1.1% | -1.6% |
| Oneness Biotech 4743.TWO | Taiwan | $652M | -21% | +37% | -510% | n/a | n/a | n/a |
| Lepu Biopharma 2157.HK | Hong Kong | $663M | -45% | +47% | 7% | 61.2× | n/a | n/a |
| Luoxin Pharmaceuticals Group Stock 002793.SZ | China | $664M | -26% | -10% | -9% | n/a | 0.3% | -17.9% |
| Sun Pharma Advanced Research SPARC.NS | India | $665M | +16% | +3,141% | 84% | n/a | n/a | n/a |
| Zhejiang Wecome Pharmaceutical 300878.SZ | China | $666M | +10% | +40% | -65% | n/a | n/a | n/a |
| Immix Biopharma IMMX | United States | $668M | -17% | n/a | n/a | n/a | n/a | n/a |
| Olema Pharmaceuticals OLMA | United States | $641M | -51% | n/a | n/a | n/a | n/a | n/a |
| FDC FDC.NS | India | $672M | +4% | +10% | 14% | n/a | 25.9% | +10.3% |
| JIANMIN PHARMACEUTICAL 600976.SS | China | $638M | -12% | -2% | 8% | 7.1× | -4.9% | +6.5% |
| Center Laboratories 4123.TWO | Taiwan | $676M | -28% | +4% | 5% | n/a | 50.8% | +16.2% |
| Hunan Fangsheng Pharmaceutical 603998.SS | China | $678M | -6% | +10% | 19% | 12.7× | -2.4% | +6.4% |
| DBV Technologies DBV.PA | France | $633M | -47% | n/a | n/a | n/a | n/a | n/a |
| Earth 4985.T | Japan | $682M | +6% | +6% | 4% | 17.7× | -2.5% | -1.8% |
| Hubei Biocause Heilen Pharmaceutical 301211.SZ | China | $682M | -5% | +13% | 4% | n/a | n/a | n/a |
| Nuvectis Pharma NVCT | United States | $683M | +79% | n/a | n/a | n/a | n/a | n/a |
| Mochida Pharmaceutical 4534.T | Japan | $683M | -6% | +15% | 9% | 15.2× | n/a | n/a |
| Jenkem Technology 688356.SS | China | $686M | -23% | +52% | 11% | 36.8× | 41.4% | +11.2% |
| Shandong Wit Dyne Health 000915.SZ | China | $687M | -33% | -36% | 36% | 9.1× | n/a | n/a |